Align Technology management check

ALGN · Health Care · Health Care Supplies · CEO Joseph Hogan

Filings as of

59
Management score, ranked 331st of 487Strongest: clean books. Weakest: CEO cost. See the best and worst run in Health Care →

4 good · 0 to watch · 2 flagged, across the seven questions below.

  • Flag

    Have owners done well?

    Trailed its chosen peers

    $100 invested at the start of fiscal 2021 grew to $29, against $117 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.76 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Flag

    What does the CEO cost owners?

    4.7% of net income

    $19.2m of reported pay in fiscal 2025, against $410.0m of net income.

  • n/a

    Do they own the stock?

    No recent CEO filing

    No open-market insider buying or selling in the last six months.

  • Good

    Are owners being diluted?

    Share count shrinking

    Diluted shares changed -2.6% a year over the last three fiscal years. Stock-based pay was 4.6% of revenue in the latest year.

  • Good

    Is leadership stable?

    8 leadership filings in 3 years

    CEO in the pay table: Joseph Hogan. 8 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    No restatements, auditor changes or late filings since 2021.

Against the S&P 500

Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.

CheckScoreAt or aboveSector median
Owner returns016%26
Pay for performance8863%85
CEO cost016%44
Skin in the game——46
Dilution8374%68
Stable leadership8561%70
Clean books100100%100

Closest peers

Others in Health Care Supplies, by management score. Align Technology is 40th of 60 in its sector.

  1. 278WSTWest Pharmaceutical Services63
  2. 321STESteris60
  3. 323MRKMerck & Co.60
  4. 325SOLVSolventum59
  5. 331ALGNAlign Technology59
  6. 333COOCooper Companies (The)59

Pay versus performance

From the proxy statement filed April 7, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.

CEO pay by fiscal yearAs reported Actually paid
−$61.3m$7.4m$76.2m20212022202320242025
What $100 becameCompany Peer group
$10020212022202320242025$29
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Joseph Hogan$19.2m$3.9m$4.3m$29$117$410.0m
2024Joseph Hogan$27.3m$5.2m$4.8m$39$110$421.0m
2023Joseph Hogan$29.0m$29.5m$4.4m$51$100$445.0m
2022Joseph Hogan$18.7m−$61.3m$3.4m$39$93$362.0m
2021Joseph Hogan$21.6m$76.2m$4.3m$123$119$772.0m

The board says pay is tied most to Net Revenues. Its other key measures: Operating Income, Stock Price.

Insiders and the CEO's stake

No open-market insider buying or selling in the last six months.

Leadership and governance on file

Latest shareholder vote results: May 20, 2026, including the say-on-pay vote.

Where the money went

Over 2021–2025: $2.2bn returned to owners in buybacks and dividends, 92% of net income, and $761.3m of pay in stock.

Fiscal year20212022202320242025
Revenue$4.0bn$3.7bn$3.9bn$4.0bn$4.0bn
Net income$772.0m$362.0m$445.0m$421.0m$410.0m
Stock-based pay$114.3m$133.4m$154.0m$173.7m$185.9m
Buybacks$375.0m$435.0m$592.4m$352.9m$465.9m
Dividends—————
Diluted shares80m78m77m75m73m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.